Quantcast
Last updated on April 20, 2014 at 19:30 EDT

New England Research Institutes, Inc (NERI) Expands Clinical Trial Services and Meets Major Milestones

June 18, 2007

New England Research Institutes, Inc (NERI), a privately held specialty contract research organization (CRO), is showcasing its expanded clinical trial services in booth number 550 at this year’s 43rd Annual Drug Information Association (DIA) Meeting in Atlanta. In addition to its ongoing research studies for private and public sector clients, NERI has secured significant new business, added a number of new employees, made advances in its long-standing patient registry work, and established a new “Center of Excellence.”

“Since starting NERI more than two decades ago, we have earned widespread recognition for our scientific credibility, efficiency and expertise in conducting clinical trials in a variety of therapeutic areas,” said President Sonja McKinlay, Ph.D. “We are pleased with the outstanding progress we have made and the clients we have served and are looking forward to offering our pharmaceutical, biotechnology, biomaterial and medical device clients more robust clinical trial and registry services than ever before, ” said McKinlay. “Plus, we have expanded services to support the increasing demand for our qualitative research assignments that have been steadily growing over the years.”

NERI has reached a number of major milestones in the following strategic areas which enhance the CRO’s clinical trial offerings:

Company Growth

NERI secured several new patient registry and clinical trial accounts focused on endocrinology and cardiovascular disease. Due to this increase in client business, NERI has created and filled 60 new positions including principle scientists, project directors, data management professionals, clinical research associates, statisticians, epidemiologists and programmers. At the senior administration level, key new hires have filled positions as Chief Scientist of Clinical Trials, Chief Scientist of Patient Registries and Clinical Director. Recruitment and hiring are ongoing to meet NERI’s continued growth and commitment to client service.

Patient Registries

“NERI has established best practices for operating patient registries,” said McKinlay. “While other CROs are just now solidifying their expertise in this area, we have been perfecting our approach since we started our business.”

NERI’s registries focus on diseases, products and health services in the highest priority therapeutic areas. NERI registries range from outcomes, post-market surveillance, CMS-mandated, and rare diseases.

NERI’s proprietary electronic data capture (EDC) system, ADEPT, has recently incorporated real-time benchmarking reports for its outcome registries. These on-line reports serve as tools to evaluate institution performance compared with other facilities, as well as assess physician performance within an institution, so that both user facilities and physicians can compare their outcomes with others in their field. ADEPT is a customizable web-based data management system that is used not only for clinical trials but also for patient registries.

“Center of Excellence”

Qualitative research methods are recognized as valuable tools for the social sciences, epidemiology, program evaluation and more traditional clinical trials. NERI recently formed the Center for Qualitative Research in response to its long track record of completing 40 qualitative studies for numerous public and private organizations. NERI’s current work in this area includes more than 12 studies on a variety of topics ranging from the pathways of care for urologic conditions to end-of-life care in the pediatric intensive care unit.

About New England Research Institutes, Inc.

New England Research Institutes, Inc. (NERI) was established in 1986 to offer impeccable research capabilities to clients in both the private and public sectors. In addition to providing specialty contract research services (i.e., customized clinical trial solutions and registry services as well as qualitative studies addressing patient reported outcomes) to pharmaceutical, biotechnology, biomaterial and medical device clients, NERI has earned widespread recognition as one of the nation’s premier public health and social science research organizations. This combination of experience gives NERI a unique scientific and marketplace advantage. For more information, visit www.neriscience.com.